

Supporting Information

Photocatalyzed Formal Carboxygenation of Terminal Alkynes

Fengjuan Chen,^a Can Yang,^a Xinwei Hu,^a Xiaoqi Zhang,^b Haisheng Xie,^a Huanfeng Jiang,^a Fubin Jiang,^c and Wei Zeng^{a,*}

^aKey Laboratory of Functional Molecular Engineering of Guangdong Province, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, China. E-mail: zengwei@scut.edu.cn

^bGuangdong Provincial Engineering Research Center for Modernization of TCM, College of Pharmacy, Jinan University, Guangzhou 510632, China

^cCollege of Chemistry, Beijing Normal University, Beijing, 100875, China

Table of Contents

I. General Experimental Information.	3
II. Preparation and Characterization of <i>N</i> -Aryl Substituted <i>N</i> -Tosylpropargylamines and <i>N</i> -Benzamido-Substituted Propargylamines (1a-1z , 1-1a , 1-1b).	3
1. Preparation of <i>N</i> -aryl substituted <i>N</i> -tosylpropargylamines and <i>N</i> -benzamido-substituted propargylamines.	3
2. Procedure for the preparation of 4-methyl- <i>N</i> -(1-phenylprop-2-yn-1-yl)- <i>N</i> -(<i>p</i> -tolyl)Benzenesulfonamide (1-1z).	7
3. Procedure for the preparation of propa-1,2-dien-1-amine (1-1c).	8
III. Screening the Reaction Conditions.	8
Table S-1. The Effect of photocatalysts on the intramolecular carboxygenation of alkyne 1a ...	8
Table S-2. The Effect of bases on the intramolecular carboxygenation of alkyne 1a	9
Table S-3. The Effect of solvents on the intramolecular carboxygenation of alkyne 1a	9
Table S-4. The Effect of the dosage of PhSSPh on the intramolecular carboxygenation of alkyne 1a	9
Table S-5. Control experiments.	10
IV. General Procedures and Characterization Data of Products.	10
1. Procedure for the photocatalyzed intramolecular carboxygenation of alkynes.	10
2. Spectroscopic data of formyl-substituted <i>N</i> -heterocycles.	11
3. Synthetic application of this transformation.	15
V. Control Experiments for Mechanistic Investigation.	16
1. The effect of the radical trapper TEMPO on the intramolecular carboxygenation of alkyne 1a	16
2. H/D exchange about the intramolecular carboxygenation of alkyne 1a	16


3. ^{18}O Isotope tracing experiment.	17
4. The procedure for the preparation of <i>d</i> 5- 1d	19
5. Kinetic isotope effect for this transformation.....	21
6. The PhSSPh-promoted intramolecular carboxygenation of alkyne 1a	23
7. The photocatalyzed intramolecular carboxygenation of alkynes 1a under argon	23
8. The vinyl thioether (<i>Z</i>)- 4a converted to target compound 2a under standard conditions	24
9. Luminescence quenching experiments	24
10. Light on/off experiments.....	25
VI. Single Crystal Structure and Crystallographic Data for 2u	26
VII. References.	26
Appendix II: Spectral Copies of ^1H and ^{13}C NMR of Compounds Obtained in This Study.	28

I. General Experimental Information


All reactions were carried out in flame-dried sealed tubes with magnetic stirring. Unless otherwise noted, all experiments were performed under in air using flash column techniques. All of the reagents were used directly as obtained commercially and used without further purification. Purifications of reaction products were carried out by flash chromatography using Qingdao Haiyang Chemical Co. Ltd silica gel (300-400 mesh). ^1H NMR and ^{13}C NMR spectra were recorded with tetramethylsilane (TMS) as internal standard at ambient temperature unless otherwise indicated on a Bruker Avance DPX 600 fourier Transform spectrometer operating at 400 or 500 MHz for ^1H NMR and 101 or 126 MHz for ^{13}C NMR. Chemical shifts are reported in parts per million (ppm) and coupling constants are reported as Hertz (Hz). Splitting patterns are designated as singlet (s), broad singlet (bs), doublet (d), triplet (t). Splitting patterns that could not be interpreted or easily visualized are designated as multiple (m). High resolution mass spectra (HR-MS) were recorded on an IF-TOF spectrometer (Micromass).

II. Preparation and characterization of *N*-aryl substituted *N*-tosylpropargylamines and *N*-benzamido-substituted propargylamines (1a-1z, 1-1a, 1-1b)

1. Preparation of *N*-aryl substituted *N*-tosylpropargylamine and *N*-benzamido-substituted propargylamines




These starting materials were prepared by using the reported method.^{1,2} To a solution of amides (1.0 equiv) in anhydrous DMF (20 mL) was added sodium hydride (60% dispersion in mineral oil, 1.1 equiv) at 0 °C under Ar. The reaction was stirred for 15 minutes at the same temperature and then 3-bromo-propyne (1.2 equiv) was slowly added *via* a syringe. The mixture was stirred at room temperature until the reaction completed and then quenched with a saturated solution of NH_4Cl (20 mL). The organic phases were washed with water (3 $\times$ 20 mL) and brine (20 mL), dried over anhydrous MgSO_4 and concentrated to obtain the corresponding residue, which was then purified through flash chromatography on silica gel with ethyl acetate/petroleum (v/v = 50/1) as the eluent to afford the desired products.



4-Methyl-*N*-(prop-2-yn-1-yl)-*N*-(*p*-tolyl)benzenesulfonamide (1a)¹: light yellow solid (807 mg, 90%); ^1H NMR (400 MHz, CDCl_3) δ 7.55 (d, J = 7.9 Hz, 2H), 7.23 (d, J = 7.8 Hz, 2H), 7.13 – 7.06 (m, 4H), 4.41 (s, 2H), 2.41 (s,


3H), 2.33 (s, 3H), 2.15 (s, 1H); ^{13}C NMR (101 MHz, CDCl_3) δ 143.6, 138.3, 136.6, 135.8, 129.7, 129.3, 128.4, 128.1, 78.2, 73.7, 41.2, 21.6, 21.2.



***N*-(4-Methoxyphenyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide**

(1b)¹: yellow solid (756 mg, 80%); ^1H NMR (400 MHz, CDCl_3) δ 7.47 (d, J = 6.1 Hz, 2H), 7.16 (d, J = 5.8 Hz, 2H), 7.03 (d, J = 6.7 Hz, 2H), 6.73 (d, J = 6.7 Hz, 2H), 4.32 (s, 2H), 3.71 (s, 3H), 2.34 (s, 3H), 2.08 (s, 1H);


^{13}C NMR (101 MHz, CDCl_3) δ 159.4, 143.6, 135.7, 131.8, 130.1, 129.3, 128.1, 114.2, 78.3, 73.7, 55.4, 41.4, 21.6.



4-Methyl-*N*-phenyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide **(1c)²**:

yellow solid (726 mg, 85%); ^1H NMR (400 MHz, CDCl_3) δ 7.54 (d, J = 7.8 Hz, 2H), 7.30 (s, 3H), 7.23 (d, J = 7.2 Hz, 4H), 4.44 (s, 2H), 2.41 (s, 3H), 2.16 (s, 1H); ^{13}C NMR (101 MHz, CDCl_3) δ 143.7, 139.4, 135.6, 129.3,


129.0, 128.5, 128.2, 128.1, 78.1, 73.8, 41.1, 21.6.



***N*-(4-Fluorophenyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide**

(1d)¹: yellow solid (799 mg, 88%); ^1H NMR (400 MHz, CDCl_3) δ 7.54 (d, J = 7.8 Hz, 2H), 7.24 (d, J = 7.8 Hz, 2H), 7.22 – 7.17 (m, 2H), 6.99 (t, J = 8.0 Hz, 2H), 4.41 (s, 2H), 2.42 (s, 3H), 2.18 (s, 1H); ^{13}C NMR (101

MHz, CDCl_3) δ 162.2 (d, J = 247 Hz, $^1J_{\text{CF}}$), 143.9, 135.4, 135.2, 135.1, 130.6 (d, J = 8 Hz, $^3J_{\text{CF}}$), 129.4, 128.0, 116.0 (d, J = 22 Hz, $^2J_{\text{CF}}$), 77.9, 74.1, 41.2, 21.6.




***N*-(4-Chlorophenyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide**

(1e)¹: yellow solid (861 mg, 90%); ^1H NMR (400 MHz, CDCl_3) δ 7.55 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 8.5 Hz, 2H), 7.26 (d, J = 7.9 Hz, 2H), 7.19 (d, J = 8.3 Hz, 2H), 4.43 (s, 2H), 2.43 (s, 3H), 2.20 (s, 1H); ^{13}C NMR (101 MHz, CDCl_3) δ 144.0, 137.9, 135.2, 134.1, 129.7, 129.5,

129.3, 128.0, 77.8, 77.4, 77.1, 76.8, 74.2, 74.2, 40.9, 21.6.

***N*-(2-Chlorophenyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide (1f)¹**: yellow solid (717 mg, 75%); ^1H NMR (400 MHz, CDCl_3) δ 7.69 (d, J = 8.1 Hz, 2H), 7.43 (d, J = 7.9 Hz, 1H), 7.35 – 7.22 (m, 5H), 4.94 – 3.96 (m, 2H), 2.43 (s, 3H), 2.17




(d, J = 2.3 Hz, 1H); ^{13}C NMR (101 MHz, CDCl_3) δ 143.9, 136.8, 135.7, 135.1, 132.6, 130.6, 130.1, 129.5, 127.9, 127.3, 77.8, 73.8, 40.1, 21.6.

***N*-(3-Chlorophenyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide**

(1g)¹: yellow solid (736 mg, 77%); ^1H NMR (400 MHz, CDCl_3) δ 7.57 (d, J = 8.3 Hz, 2H), 7.34 – 7.24 (m, 5H), 7.20 – 7.15 (m, 1H), 4.44 (d, J = 2.5 Hz, 2H), 2.44 (s, 3H), 2.21 (t, J = 2.5 Hz, 1H); ^{13}C NMR (101 MHz, CDCl_3)


δ 144.1, 140.6, 135.2, 134.4, 129.9, 129.5, 128.5, 128.4, 128.0, 126.4, 77.7, 74.3, 40.9, 21.6.



***N*-(4-Bromophenyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide**

(1h)¹: yellow solid (890 mg, 80%); ^1H NMR (400 MHz, CDCl_3) δ 7.53 (d, J = 8.2 Hz, 2H), 7.43 (d, J = 8.5 Hz, 2H), 7.24 (d, J = 8.1 Hz, 2H), 7.11 (d, J = 8.6 Hz, 2H), 4.40 (d, J = 2.4 Hz, 2H), 2.41 (s, 3H), 2.18 (t, J = 2.4 Hz, 1H);


^{13}C NMR (101 MHz, CDCl_3) δ 144.0, 138.4, 135.2, 132.2, 130.0, 129.5, 128.0, 122.1, 77.7, 74.2, 40.9, 21.6.




4-Methyl-*N*-(prop-2-yn-1-yl)-*N*-(4-(trifluoromethyl)phenyl)benzenesulfonamide

(1i)¹: yellow solid (794 mg, 75%); ^1H NMR (400 MHz, CDCl_3) δ 7.58 (d, J = 8.3 Hz, 2H), 7.54 (d, J = 8.1 Hz, 2H), 7.40 (d, J = 8.3 Hz, 2H),


7.25 (d, $J = 8.0$ Hz, 2H), 4.46 (d, $J = 2.3$ Hz, 2H), 2.40 (s, 3H), 2.20 (d, $J = 2.2$ Hz, 1H); ^{13}C NMR (101 MHz, CDCl_3) δ 144.3, 142.7, 137.9, 135.1, 129.9, 129.6, 128.0, 127.9 (d, $J = 5$ Hz, $^3J_{\text{CF}}$), 126.1 (q, $J = 4$ Hz, $^3J_{\text{CF}}$), 123.8 (d, $J = 270$ Hz, $^1J_{\text{CF}}$), 77.5, 74.4, 40.6, 21.5.




***N*-(3,4-Dimethylphenyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide (1j)**¹: yellow solid (788 mg, 84%); ^1H NMR (400 MHz, CDCl_3) δ 7.60 (d, $J = 8.1$ Hz, 2H), 7.26 (d, $J = 8.1$ Hz, 2H), 7.06 (d, $J = 8.3$ Hz, 2H), 6.90 (dd, $J = 8.0, 1.7$ Hz, 1H), 4.42 (d, $J = 2.4$ Hz, 2H), 2.44 (s, 3H), 2.26 (s, 3H), 2.23 (s, 3H), 2.18 (t, $J = 2.3$ Hz, 1H); ^{13}C NMR (101 MHz, CDCl_3) δ 143.6, 137.5, 137.0, 136.9, 135.9, 130.1, 129.9, 129.2, 128.1, 125.5, 78.3, 73.6, 41.2, 21.6, 19.8, 19.5.




***N*-(4-Chloro-3-methylphenyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide (1k)**¹: yellow solid (789 mg, 79%); ^1H NMR (400 MHz, CDCl_3) δ 7.57 (d, $J = 8.2$ Hz, 1H), 7.27 (d, $J = 8.4$ Hz, 3H), 7.18 (d, $J = 2.4$ Hz, 1H), 6.95 (dd, $J = 8.5, 2.5$ Hz, 1H), 4.42 (d, $J = 2.5$ Hz, 2H), 2.44 (s, 3H), 2.35 (s, 3H), 2.19 (t, $J = 2.4$ Hz, 1H); ^{13}C NMR (101 MHz, CDCl_3) δ 143.9, 137.7, 137.1, 135.4, 134.3, 131.2, 129.5, 129.4, 128.0, 126.7, 77.9, 74.0, 41.0, 21.6, 20.1.




***N*-(3-Fluoro-4-methylphenyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide (1l)**¹: yellow solid (827 mg, 87%); ^1H NMR (400 MHz, CDCl_3) δ 7.58 (d, $J = 8.0$ Hz, 2H), 7.27 (d, $J = 8.0$ Hz, 2H), 7.13 (t, $J = 8.2$ Hz, 1H), 6.95 (d, $J = 9.2$ Hz, 2H), 4.43 (d, $J = 1.4$ Hz, 2H), 2.44 (s, 3H), 2.28 (s, 3H), 2.20 (s, 1H); ^{13}C NMR (101 MHz, CDCl_3) δ 160.7 (d, $J = 245$ Hz, $^1J_{\text{CF}}$), 143.9, 138.2 (d, $J = 10$ Hz, $^3J_{\text{CF}}$), 135.4, 131.4 (d, $J = 6$ Hz, $^3J_{\text{CF}}$), 129.4, 128.0, 125.2 (d, $J = 17$ Hz, $^2J_{\text{CF}}$), 123.8 (d, $J = 4$ Hz, $^3J_{\text{CF}}$), 115.2 (d, $J = 24$ Hz, $^2J_{\text{CF}}$), 77.9, 74.0, 41.0, 21.6, 14.3.




4-Methyl-*N*-(naphthalen-1-yl)-*N*-(prop-2-yn-1-yl)benzenesulfonamide (1m)¹: yellow solid (502 mg, 50%); ^1H NMR (400 MHz, CDCl_3) δ 8.18 (d, $J = 8.0$ Hz, 1H), 7.84 (d, $J = 7.9$ Hz, 2H), 7.69 (d, $J = 7.8$ Hz, 2H), 7.58 – 7.45 (m, 2H), 7.32 (t, $J = 7.7$ Hz, 1H), 7.26 (d, $J = 7.8$ Hz, 2H), 7.09 (d, $J = 7.2$ Hz, 1H), 4.80 (d, $J = 17.8$ Hz, 1H), 4.29 (d, $J = 17.8$ Hz, 1H), 2.43 (s, 3H), 2.11 (s, 1H); ^{13}C NMR (101 MHz, CDCl_3) δ 143.8, 136.2, 135.5, 134.8, 132.5, 129.5, 129.4, 128.3, 128.1, 127.2, 127.1, 126.6, 124.9, 123.7, 78.2, 73.9, 41.7, 21.6.




***N*-Isopropyl-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide (1n)**¹: yellow liquid (647 mg, 86%); ^1H NMR (400 MHz, CDCl_3) δ 7.80 (d, $J = 8.3$ Hz, 2H), 7.29 (d, 2H), 4.14 (dd, $J = 13.6, 6.8$ Hz, 1H), 4.09 (d, $J = 2.5$ Hz, 2H), 2.43 (s, 3H), 2.17 (t, $J = 2.5$ Hz, 1H), 1.17 (s, 3H), 1.15 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 143.2, 137.9, 129.4, 127.4, 80.4, 72.2, 49.8, 31.3, 21.5, 20.8.



***N*-Cyclopropyl-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide (1o)**¹: yellow solid (575 mg, 77%); ^1H NMR (400 MHz, CDCl_3) δ 7.81 (d, $J = 8.3$ Hz, 2H), 7.30 (d, $J = 8.1$ Hz, 2H), 4.12 (d, $J = 2.5$ Hz, 2H), 2.43 (s, 3H), 2.20 (tt, $J = 6.9, 3.6$ Hz, 1H), 2.04 – 1.96 (m, 1H), 0.95 – 0.90 (m, 2H), 0.79 – 0.70 (m, 2H); ^{13}C NMR (101 MHz, CDCl_3) δ 143.7, 135.0, 129.3, 128.4, 77.1, 73.8, 39.8, 29.3, 21.6, 7.7.




4-Methoxy-*N*-(prop-2-yn-1-yl)-*N*-(p-tolyl)benzenesulfonamide (1p)¹: yellow solid (765 mg, 81%); ^1H NMR (400 MHz, CDCl_3) δ 7.58 (d, $J = 8.5$ Hz, 2H), 7.10 (s, 4H), 6.89 (d, $J = 8.5$ Hz, 2H), 4.39 (s, 2H), 3.84 (s, 3H), 2.32 (s, 3H), 2.17 (s, 1H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.1, 138.2, 136.7, 130.2, 130.2, 129.7, 128.4, 113.8, 78.3, 73.8, 55.6, 41.1, 21.2.




***N*-(Prop-2-yn-1-yl)-*N*-(*p*-tolyl)-[1,1'-biphenyl]-4-sulfonamide (1q)¹:**

yellow solid (758 mg, 70%); ¹H NMR (400 MHz, CDCl₃) δ 7.73 (d, *J* = 7.9 Hz, 2H), 7.65 (d, *J* = 7.7 Hz, 2H), 7.60 (d, *J* = 7.3 Hz, 2H), 7.46 (t, *J* = 7.0 Hz, 2H), 7.42 – 7.36 (m, 1H), 7.16 – 7.08 (m, 4H), 4.45 (s, 2H), 2.33 (s, 3H), 2.17 (s, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 145.6, 139.3, 138.4, 137.3, 136.6, 129.8, 129.1, 128.6, 128.6, 128.5, 127.3, 127.2, 78.2, 73.9, 41.3, 21.2.




4-Fluoro-*N*-(prop-2-yn-1-yl)-*N*-(*p*-tolyl)benzenesulfonamide (1r)¹:

yellow solid (718 mg, 79%); ¹H NMR (400 MHz, CDCl₃) δ 7.69 (s, 2H), 7.19 – 7.03 (m, 6H), 4.43 (s, 2H), 2.35 (s, 3H), 2.18 (s, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 165.2 (d, *J* = 253 Hz, ¹J_{CF}), 138.6, 136.5, 134.8 (d, *J* = 4 Hz, ³J_{CF}), 134.8, 130.8 (d, *J* = 9 Hz, ³J_{CF}), 129.9, 128.4, 115.9 (d, *J* = 23 Hz, ²J_{CF}), 78.1, 74.0, 41.3, 21.2.




4-Chloro-*N*-(prop-2-yn-1-yl)-*N*-(*p*-tolyl)benzenesulfonamide (1s)¹:

yellow solid (765 mg, 80%); ¹H NMR (400 MHz, CDCl₃) δ 7.61 (d, *J* = 8.3 Hz, 2H), 7.41 (d, *J* = 8.4 Hz, 2H), 7.12 (s, 4H), 4.43 (s, 2H), 2.34 (s, 3H), 2.19 (s, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 139.3, 138.6, 137.3, 136.4, 129.9, 129.5, 128.9, 128.4, 78.0, 74.1, 41.4, 21.2.




3-Chloro-*N*-(prop-2-yn-1-yl)-*N*-(*p*-tolyl)benzenesulfonamide (1t)¹:

yellow solid (727 mg, 76%); ¹H NMR (400 MHz, CDCl₃) δ 7.72 (s, 1H), 7.52 (d, *J* = 7.8 Hz, 2H), 7.37 (t, *J* = 7.8 Hz, 1H), 7.15 – 7.07 (m, 4H), 4.43 (s, 2H), 2.34 (s, 3H), 2.21 (s, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 140.4, 138.8, 136.3, 134.8, 132.9, 130.0, 129.9, 128.4, 128.1, 126.2, 77.9, 74.2, 41.5, 21.2.




4-Chloro-*N*-phenyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide (1u)²:

yellow solid (677 mg, 74%); ¹H NMR (400 MHz, CDCl₃) δ 7.60 (d, *J* = 8.4 Hz, 2H), 7.41 (d, *J* = 8.3 Hz, 2H), 7.33 (d, *J* = 2.5 Hz, 3H), 7.26 (d, *J* = 2.3 Hz, 2H), 4.46 (s, 2H), 2.20 (s, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 139.4, 139.2, 137.2, 129.5, 129.2, 128.9, 128.5, 128.4, 77.9, 74.2, 41.3.




4-Bromo-*N*-(prop-2-yn-1-yl)-*N*-(*p*-tolyl)benzenesulfonamide (1v)¹:

yellow solid (857 mg, 79%); ¹H NMR (400 MHz, CDCl₃) δ 7.58 (d, *J* = 8.2 Hz, 2H), 7.53 (d, *J* = 8.3 Hz, 2H), 7.15 – 7.08 (m, 4H), 4.42 (s, 2H), 2.34 (s, 3H), 2.19 (s, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 138.7, 137.9, 136.4, 131.9, 129.9, 129.6, 128.4, 127.9, 78.0, 74.1, 41.4, 21.2.




***N*-(Prop-2-yn-1-yl)-*N*-(*p*-tolyl)-4-(trifluoromethyl)benzenesulfonamide (1w)¹:**

yellow solid (847 mg, 80%); ¹H NMR (400 MHz, CDCl₃) δ 7.82 (d, *J* = 8.2 Hz, 2H), 7.71 (d, *J* = 8.2 Hz, 2H), 7.18 – 7.06 (m, 4H), 4.46 (s, 2H), 2.35 (s, 3H), 2.18 (s, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 142.5, 138.9, 136.3, 134.4 (d, *J* = 32 Hz, ²J_{CF}), 130.0, 128.6, 128.3, 125.8 (q, *J* = 4 Hz, ³J_{CF}), 123.3 (q, *J* = 271 Hz, ¹J_{CF}), 77.8, 74.2, 41.5, 21.2.




3-Chloro-4-methyl-*N*-(prop-2-yn-1-yl)-*N*-(*p*-tolyl)benzenesulfonamide (1x)¹:

yellow solid (819 mg, 82%); ¹H NMR (400 MHz, CDCl₃) δ 7.71 (s, 1H), 7.41 (d, *J* = 7.9 Hz, 1H), 7.28 (d, *J* = 8.0 Hz, 1H), 7.15 – 7.08 (m, 4H), 4.42 (s, 2H), 2.43 (s, 3H), 2.34 (s, 3H), 2.21 (s, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 141.6, 138.6, 137.7, 136.4, 134.8, 131.0, 129.9, 128.6, 128.4, 126.2, 78.0, 74.0, 41.4, 21.2, 20.3.




3-Fluoro-4-methyl-N-(prop-2-yn-1-yl)-N-(p-tolyl)benzenesulfonamide


(1y)¹: yellow solid (1.093 g, 69%); ¹H NMR (400 MHz, CDCl₃) δ 7.38 (d, *J* = 8.4 Hz, 2H), 7.29 (d, *J* = 6.9 Hz, 1H), 7.18 – 7.11 (m, 4H), 4.45 (s, 2H), 2.37 (s, 6H), 2.22 (s, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 160.5 (d, *J* = 248 Hz, ³¹J_{CF}), 138.6, 137.9 (d, *J* = 7 Hz, ³J_{CF}), 136.4, 131.7 (d, *J* = 5 Hz, ³J_{CF}), 130.7 (d, *J* = 17 Hz, ²J_{CF}), 129.8, 128.4, 123.6 (d, *J* = 4 Hz, ³J_{CF}), 114.9 (d, *J* = 26 Hz, ²J_{CF}), 78.0, 73.9, 41.4, 21.2, 14.8.



N-(Prop-2-yn-1-yl)-N-(p-tolyl)pyridine-3-sulfonamide (1z)¹: brown solid (729 mg, 51%); ¹H NMR (400 MHz, CDCl₃) δ 8.89 (s, 1H), 8.78 (d, *J* = 3.1 Hz, 1H), 7.94 (d, *J* = 7.9 Hz, 1H), 7.43 – 7.37 (m, 1H), 7.14 (s, 4H), 4.46 (s, 2H), 2.34 (s, 3H), 2.23 (s, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 153.2, 148.7, 138.9, 136.2, 135.8, 135.5, 130.0, 128.2, 123.3, 77.8, 74.5, 41.5, 21.1.




N-(Prop-2-yn-1-yl)-N-(p-tolyl)benzamide (1-1a)¹: white solid (821 mg, 66%); ¹H NMR (400 MHz, CDCl₃) δ 7.34 (d, *J* = 7.3 Hz, 2H), 7.24 (t, 1H), 7.16 (t, *J* = 7.3 Hz, 2H), 7.02 (q, *J* = 8.3 Hz, 4H), 4.65 (s, 2H), 2.27 (s, 3H), 2.24 (s, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 170.2, 140.2, 137.1, 135.3, 129.9, 128.8, 127.7, 127.5, 79.2, 77.4, 72.2, 39.9, 21.1.




N-(But-2-yn-1-yl)-4-methyl-N-(p-tolyl)benzenesulfonamide (1-1b)¹: yellow solid (1.283g, 82%); ¹H NMR (400 MHz, CDCl₃) δ 7.54 (d, *J* = 8.0 Hz, 2H), 7.22 (d, *J* = 7.9 Hz, 2H), 7.10 (s, 4H), 4.35 (s, 2H), 2.41 (s, 3H), 2.33 (s, 3H), 1.64 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 143.3, 137.9, 137.2, 136.1, 129.6, 129.1, 128.3, 128.1, 81.5, 73.5, 41.8, 21.6, 21.1, 3.5; **HR-MS (ESI)** calcd for [M + Na]⁺: C₁₈H₁₉NO₂SNa: 336.1029, found: 336.1055.

2. Procedure for the preparation of 4-methyl-N-(1-phenylprop-2-yn-1-yl)-N-(p-tolyl)benzenesulfonamide (1-1z)³




This starting material **1-1z** was prepared by using the reported method.³ To a mixture of 4-methyl-N-(p-tolyl)benzenesulfonamide (0.9 mmol), PPh₃ (1.0 mmol), and 1-phenylprop-2-yn-1-ol (1.0 mmol) in THF (5.0 mL) was added DEAD (2.20 M in toluene, 1.0 mmol) at 0 °C. The mixture was stirred at reflux for 6 h and cooled to room temperature. After THF was removed under reduced pressure, the residue was chromatographed on silica gel (hexane-ethyl acetate) to afford 4-methyl-N-(1-phenylprop-2-yn-1-yl)-N-(p-tolyl)benzenesulfonamide **1-1z**.




4-Methyl-N-(1-phenylprop-2-yn-1-yl)-N-(p-tolyl)benzenesulfonamide (1-1z)¹: yellow solid (562 mg, 30%); ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, *J* = 7.6 Hz, 2H), 7.41 (s, 2H), 7.33 – 7.24 (m, 5H), 6.93 (d, *J* = 7.5 Hz, 2H), 6.74 (d, *J* = 7.7 Hz, 2H), 6.56 (s, 1H), 2.51 (s, 1H), 2.47 (s, 3H), 2.27 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 143.4, 138.6, 137.0, 135.9, 132.7, 131.5, 129.3, 129.1, 128.6, 128.3, 128.2, 128.1, 79.8, 54.8, 21.6, 21.2; **HR-MS (ESI)** calcd for [M + Na]⁺: C₂₃H₂₁NO₂SNa: 398.1185, found: 398.1224.

3. Procedure for the preparation of propa-1,2-dien-1-amine (1-1c) ⁴



This starting material **1-1c** was prepared by using the reported method.⁴ A flame-dried flask filled with argon was charged with corresponding 4-methyl-*N*-(prop-2-yn-1-yl)-*N*-(*p*-tolyl)benzenesulfonamide **1a** (1.0 equiv), and the flask was then closed by a septum. Back-filled with a flow of argon. Argon atmosphere was ensured by argon balloon. Solid was dissolved in DMF (10 mL), and then sodium hydroxide (1.2 equiv) was added quickly. After 12 hours, the solution was neutralized with adding of saturated solution of ammonium chloride (30 mL), the corresponding aqueous phase was extracted with CH₂Cl₂ (3 × 20 mL). The combined organic solution was dried with MgSO₄ and the solvents were removed under reduced pressure. The crude product was then purified by flash column chromatography to obtain corresponding allenamide **1-1c**.



4-Methyl-*N*-(propa-1,2-dien-1-yl)-*N*-(*p*-tolyl)benzenesulfonamide

(1-1c): white solid (822 mg, 55%); ¹H NMR (400 MHz, CDCl₃) δ 7.56 (d, *J* = 7.5 Hz, 2H), 7.27 (d, *J* = 7.6 Hz, 2H), 7.09 (t, *J* = 10.1 Hz, 3H), 6.87 (d, *J* = 7.4 Hz, 2H), 5.05 – 5.00 (m, 2H), 2.44 (s, 3H), 2.32 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 201.1, 143.9, 138.7, 135.3, 134.5,

129.6, 129.5, 129.3, 127.7, 102.5, 87.5, 21.7, 21.2; **HR-MS (ESI)** calcd for [M + H]⁺: C₁₇H₁₈NO₂S: 300.1053, found: 300.1078.

III. Screening the reaction conditions

Table S-1. The Effect of photocatalysts on the intramolecular carbo-oxygenation of alkyne 1a^a

Entry	Photocatalyst	Yield (%) ^b
1	PC-1	32
2	PC-2	29
3	Eosin Y	75
4	TPT	65
5	Ru(bpy) ₃ Cl ₂	10
6	<i>fac</i> -Ir(ppy) ₃	30

^a0.10 mmol of *N*-propargyl-*N*-tosylamide (**1a**) (29.9 mg), H₂O (0.50 mmol), photocatalyst (2.5 mol %), K₂CO₃ (1.5 equiv.), and PhSSPh (0.10 mmol) in DCE (2.0 mL) under an air atmosphere at room temperature for 24 h, blue LED light. ^bIsolated yield.

Table S-2. The Effect of bases on the intramolecular carbo-oxygenation of alkyne **1a^a**

Entry	Base	Yield (%) ^b
1	CH ₃ COOK	34
2	Na ₂ CO ₃	40
3	CH ₃ COONa	0
4	K ₃ PO ₄	54
5	KPF ₆	14
6	^t BuONa	60
7	Cs ₂ CO ₃	36
8	Li ₂ CO ₃	10


^a0.10 mmol of *N*-propargyl-*N*-tosylamide (**1a**) (29.9 mg), H₂O (0.50 mmol), Eosin Y (2.5 mol %), base (1.5 equiv.), and PhSSPh (0.10 mmol) in DCE (2.0 mL) under an air atmosphere at room temperature for 24 h, blue LED light. ^bIsolated yield.

Table S-3. The Effect of solvents on the intramolecular carbo-oxygenation of alkyne **1a^a**

Entry	Base	Yield (%) ^b
1	Toluene	40
2	CH ₃ CN	50
3	THF	0
4	DCM	0
5	CHCl ₃	0
6	CHCl ₂ CHCl ₂	0
7	CH ₂ BrCH ₂ Br	0

^a0.10 mmol of *N*-propargyl-*N*-tosylamide (**1a**) (29.9 mg), H₂O (0.50 mmol), Eosin Y (2.5 mol %), K₂CO₃ (1.5 equiv.), and PhSSPh (0.10 mmol) in solvent (2.0 mL) under an air atmosphere at room temperature for 24 h, blue LED light. ^bIsolated yield.

Table S-4. The Effect of the dosage of PhSSPh on the intramolecular carbo-oxygenation of alkyne **1a^a**



Entry	PhSSPh (x equiv.)	Yield (%) ^b
1	0.1	15
2	0.3	31
3	0.5	47
4	1.0	75

^a0.10 mmol of *N*-propargyl-*N*-tosylamide (**1a**) (29.9 mg), H₂O (0.50 mmol), Eosin Y (2.5 mol %), K₂CO₃ (1.5 equiv.), and PhSSPh (0.10 -1.0 mmol) in DCE (2.0 mL) under an air atmosphere at room temperature for 24 h, blue LED light. ^bIsolated yield.

Table S-5. Control experiments^a


Reaction scheme showing the photocatalyzed intramolecular carbo-oxygenation of *N*-propargyl-*N*-tosylamide (**1a**) to form product **2a**. Reagents: Eosin Y (2.5 mol%), PhSSPh (100 mol%), K₂CO₃/H₂O, DCE, air, 30 W Blue LEDs, rt, 24 h.

Entry	Changes to standard conditions	Yield (%) ^b
1	none	75
2	no photocatalyst	48
3	no PhSSPh	0
4	no light	0
5	no base	0
6	Ar instead of O ₂	0
7	without H ₂ O	48

^a0.10 mmol of *N*-propargyl-*N*-tosylamide (**1a**) (29.9 mg), H₂O (0.50 mmol), Eosin Y (2.5 mol %), K₂CO₃ (1.5 equiv.), and PhSSPh (1.0 equiv) in DCE (2.0 mL) under an air atmosphere at room temperature for 24 h, blue LED light. ^bIsolated yield.

IV. General Procedure and Characterization Data of the Products

1. Procedure for the photocatalyzed intramolecular carbo-oxygenation of alkynes




A flame-dried 5 mL Schlenk tube equipped with a magnetic stirrer bar was charged sequentially with *N*-propargyl-*N*-tosylamides (**1**, 0.10 mmol, 29.9 mg), Eosin Y (2.5 mol %, 1.8 mg), K₂CO₃ (1.5 equiv, 20.7 mg), PhSSPh (0.10 mmol, 21.8 mg) and H₂O (0.50 mmol, 9.0 uL), followed by the addition of DCE (2.0 mL) under air. Then the mixture was stirred and irradiated with 2 × 30 W blue LEDs at room temperature for 24 h. The residue was purified by flash column

chromatography on silica gel (petrol ether/EtOAc = 20/1) to afford the desired products 2.

2. Spectroscopic data of formyl-substituted *N*-heterocycles


6-Methyl-2-(*p*-tolyl)-2H-benzo[e][1,2]thiazine-4-carbaldehyde



1,1-dioxide (2a): yellow solid (23.5 mg, 75%); m.p. 168.5-169.3 °C;

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 9.58 (s, 1H), 8.68 (s, 1H), 7.90 (d, J = 8.2 Hz, 1H), 7.39 (dd, J = 17.5, 8.9 Hz, 4H), 7.31 (d, J = 8.0 Hz, 2H), 2.52 (s, 3H), 2.43 (s, 3H); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 188.2,


150.0, 144.3, 140.3, 133.7, 130.6, 129.6, 129.3, 127.4, 127.3, 126.2, 122.6, 115.9, 22.1, 21.3; **HR-MS (ESI)** calcd for $[\text{M} + \text{H}]^+$: $\text{C}_{17}\text{H}_{16}\text{NO}_3\text{S}$: 314.0845, found: 314.0843.



2-(4-Methoxyphenyl)-6-methyl-2H-benzo[e][1,2]thiazine-4-carbaldehyde 1,1-dioxide (2b): yellow solid (22.4 mg, 68%); m.p.

163.5-165.5 °C; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 9.57 (s, 1H), 8.69 (s, 1H), 7.90 (d, J = 8.2 Hz, 1H), 7.42 (t, J = 7.2 Hz, 3H), 7.34 (s, 1H), 7.01 (d, J = 8.4 Hz, 2H), 3.86 (s, 3H), 2.52 (s, 3H); $^{13}\text{C NMR}$ (101

MHz, CDCl_3) δ 188.1, 160.8, 150.3, 144.3, 129.6, 129.3, 129.3, 128.7, 127.2, 126.2, 122.7, 115.7, 115.1, 55.7, 22.1; **HR-MS (ESI)** calcd for $[\text{M} + \text{H}]^+$: $\text{C}_{17}\text{H}_{16}\text{NO}_4\text{S}$: 330.0795, found: 330.0793.




6-Methyl-2-phenyl-2H-benzo[e][1,2]thiazine-4-carbaldehyde

1,1-dioxide (2c): yellow solid (17.6 mg, 59%); m.p. 163.5-164.3 °C;

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 9.59 (s, 1H), 8.68 (s, 1H), 7.90 (d, J = 8.2 Hz, 1H), 7.56 – 7.47 (m, 5H), 7.41 (d, J = 8.1 Hz, 1H), 7.38 (s, 1H), 2.52 (s, 3H); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 188.2, 149.6, 144.4,


136.4, 130.0, 129.8, 129.7, 129.2, 127.5, 127.4, 126.2, 122.6, 116.2, 22.1; **HR-MS (ESI)** calcd for $[\text{M} + \text{H}]^+$: $\text{C}_{16}\text{H}_{14}\text{NO}_3\text{S}$: 300.0689, found: 300.0687.



2-(4-Fluorophenyl)-6-methyl-2H-benzo[e][1,2]thiazine-4-carbaldehyde 1,1-dioxide (2d): yellow solid (19.7 mg, 62%); m.p. 140.5-141.3

°C; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 9.50 (s, 1H), 8.58 (s, 1H), 7.80 (d, J = 8.1 Hz, 1H), 7.41 (s, 2H), 7.33 (d, J = 8.1 Hz, 1H), 7.26 (s, 1H), 7.12 (t, J = 8.0 Hz, 2H), 2.43 (s, 3H); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 188.1, 163.2 (d, J = 250 Hz, $^1J_{\text{CF}}$), 149.5, 144.5, 132.1 (d, J = 4 Hz,


$^3J_{\text{CF}}$), 129.9, 129.8, 129.1, 127.2, 126.3, 122.6, 117.0 (d, J = 23 Hz, $^2J_{\text{CF}}$), 116.2, 22.1; **HR-MS (ESI)** calcd for $[\text{M} + \text{H}]^+$: $\text{C}_{16}\text{H}_{13}\text{FNO}_3\text{S}$: 318.0595, found: 318.0594.



2-(4-Chlorophenyl)-6-methyl-2H-benzo[e][1,2]thiazine-4-carbaldehyde 1,1-dioxide (2e): yellow solid (21.6 mg, 65%); m.p. 165.5-167.3

°C; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 9.63 (s, 1H), 8.69 (s, 1H), 7.92 (d, J = 8.2 Hz, 1H), 7.54 – 7.50 (m, 2H), 7.49 – 7.43 (m, 3H), 7.36 (s, 1H), 2.55 (s, 3H); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 188.0, 149.0, 144.6,


136.0, 134.8, 130.2, 129.8, 129.1, 128.8, 127.3, 126.4, 122.6, 116.6, 22.1; **HR-MS (ESI)** calcd for $[\text{M} + \text{H}]^+$: $\text{C}_{16}\text{H}_{13}\text{ClNO}_3\text{S}$: 334.0299, found: 334.0297.




2-(2-Chlorophenyl)-6-methyl-2H-benzo[e][1,2]thiazine-4-carbaldehyde 1,1-dioxide (2f): yellow solid (17.0 mg, 51%); m.p. 160.7-161.3

°C; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 9.62 (s, 1H), 8.71 (s, 1H), 7.93 (d, J = 8.1 Hz, 1H), 7.77 (d, J = 7.7 Hz, 1H), 7.60 (d, J = 7.9 Hz, 1H), 7.55 – 7.42 (m, 3H), 7.31 (s, 1H), 2.55 (s, 3H); $^{13}\text{C NMR}$ (101 MHz, CDCl_3)


δ 188.2, 149.9, 144.4, 133.8, 133.3, 131.7, 131.2, 131.2, 129.7, 129.2, 128.2, 127.9, 126.5, 122.4, 116.5, 22.1; **HR-MS (ESI)** calcd for $[M + H]^+$: $C_{16}H_{13}ClNO_3S$: 334.0299, found: 334.0302.




2-(3-Chlorophenyl)-6-methyl-2H-benzo[e][1,2]thiazine-4-carbaldehyde 1,1-dioxide (2g): yellow solid (21.6 mg, 65%); m.p. 130.5-131.3 °C; 1H NMR (400 MHz, $CDCl_3$) δ 9.63 (s, 1H), 8.68 (s, 1H), 7.89 (dd, J = 21.3, 8.2 Hz, 1H), 7.51 (d, J = 8.1 Hz, 2H), 7.46 (t, J = 8.0 Hz, 3H), 7.38 (s, 1H), 2.55 (s, 3H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 188.1, 148.8, 144.6, 137.3, 135.6, 130.8, 130.02, 129.9, 129.0, 127.6, 127.4, 126.4, 125.6, 122.6, 116.8, 22.1; **HR-MS (ESI)** calcd for $[M + H]^+$: $C_{16}H_{13}ClNO_3S$: 334.0299, found: 334.0301.




2-(4-Bromophenyl)-6-methyl-2H-benzo[e][1,2]thiazine-4-carbaldehyde 1,1-dioxide (2h): yellow solid (24.1 mg, 64%); m.p. 182.5-184.3 °C; 1H NMR (400 MHz, $CDCl_3$) δ 9.62 (s, 1H), 8.68 (s, 1H), 7.91 (d, J = 8.1 Hz, 1H), 7.67 (d, J = 7.6 Hz, 2H), 7.44 (d, J = 8.1 Hz, 1H), 7.39 (d, J = 7.7 Hz, 2H), 7.36 (s, 1H), 2.54 (s, 3H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 188.1, 148.9, 144.6, 135.3, 133.2, 129.8, 129.1, 129.0, 127.3, 126.4, 124.0, 122.6, 116.6, 22.1; **HR-MS (ESI)** calcd for $[M + H]^+$: $C_{16}H_{13}BrNO_3S$: 377.9794, found: 377.9794.




6-Methyl-2-(4-(trifluoromethyl)phenyl)-2H-benzo[e][1,2]thiazine-4-carbaldehyde 1,1-dioxide (2i): yellow solid (20.2 mg, 55%); m.p. 168.5-169.3 °C; 1H NMR (400 MHz, $CDCl_3$) δ 9.64 (s, 1H), 8.66 (s, 1H), 7.91 (d, J = 8.0 Hz, 1H), 7.80 (d, J = 7.8 Hz, 2H), 7.64 (d, J = 7.9 Hz, 2H), 7.44 (d, J = 8.0 Hz, 1H), 7.37 (s, 1H), 2.53 (s, 3H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 188.0, 148.2, 144.7, 139.4, 131.6 (d, J = 33 Hz, $^2J_{CF}$), 130.0, 129.0, 127.5, 127.4, 127.6 (q, J = 4 Hz, $^3J_{CF}$), 126.7, 126.5, 122.6, 117.3, 22.1; **HR-MS (ESI)** calcd for $[M + H]^+$: $C_{17}H_{13}F_3NO_3S$: 368.0563, found: 368.0560.



2-(3,4-Dimethylphenyl)-6-methyl-2H-benzo[e][1,2]thiazine-4-carbaldehyde 1,1-dioxide (2j): yellow solid (21.9 mg, 67%); m.p. 164.5-165.3 °C; 1H NMR (400 MHz, $CDCl_3$) δ 9.58 (s, 1H), 8.70 (s, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.42 (d, J = 8.2 Hz, 1H), 7.38 (s, 1H), 7.31 – 7.24 (m, 3H), 2.53 (s, 3H), 2.34 (s, 6H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 188.2, 150.1, 144.2, 139.0, 138.7, 133.9, 130.9, 129.6, 129.3, 128.5, 127.3, 126.1, 124.9, 122.6, 115.7, 22.1, 22.1, 19.8, 19.6; **HR-MS (ESI)** calcd for $[M + H]^+$: $C_{18}H_{18}NO_3S$: 328.1002, found: 328.0996.




2-(4-Chloro-3-methylphenyl)-6-methyl-2H-benzo[e][1,2]thiazine-4-carbaldehyde 1,1-dioxide (2k): yellow solid (22.2 mg, 64%); m.p. 152.5-154.3 °C; 1H NMR (400 MHz, $CDCl_3$) δ 9.49 (s, 1H), 8.56 (s, 1H), 7.78 (d, J = 8.2 Hz, 1H), 7.37 (d, J = 8.5 Hz, 1H), 7.32 (d, J = 8.2 Hz, 1H), 7.29 (d, J = 1.9 Hz, 1H), 7.25 (s, 1H), 7.20 – 7.16 (m, 1H), 2.42 (s, 3H), 2.33 (s, 3H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 188.1, 149.3, 144.5, 138.3, 136.1, 134.6, 130.4, 129.8, 129.1, 127.3, 126.3, 126.1, 122.6, 116.3, 22.1, 20.2; **HR-MS (ESI)** calcd for $[M + H]^+$: $C_{17}H_{15}ClNO_3S$: 348.0456, found: 348.0456.




2-(3-Fluoro-4-methylphenyl)-6-methyl-2H-benzo[e][1,2]thiazine-4-carbaldehyde 1,1-dioxide (2l): yellow solid (20.9 mg, 63%); m.p. 147.5-148.3 °C; 1H NMR (400 MHz, $CDCl_3$) δ 9.50 (s, 1H), 8.57 (s, 1H), 7.80 (d, J = 8.2 Hz, 1H), 7.33 (d, J = 8.1 Hz, 1H), 7.27 – 7.21 (m, 2H), 7.14 – 7.08 (m, 2H), 2.43 (s, 3H), 2.25 (s, 3H); ^{13}C NMR (101


MHz, CDCl₃) δ 188.1, 161.1 (d, J = 247 Hz, $^1J_{\text{CF}}$), 149.3, 144.5, 134.8, 134.7, 132.4 (d, J = 6 Hz, $^3J_{\text{CF}}$), 129.8, 129.1, 127.4, 127.3, 127.2, 126.3, 123.0 (d, J = 3 Hz, $^3J_{\text{CF}}$), 122.6, 116.4, 114.7 (d, J = 24 Hz, $^2J_{\text{CF}}$), 22.1, 14.4; **HR-MS (ESI)** calcd for $[\text{M} + \text{H}]^+$: C₁₇H₁₅FNO₃S: 332.0751, found: 332.0748.




6-Methyl-2-(naphthalen-1-yl)-2H-benzo[e][1,2]thiazine-4-carbaldehyde 1,1-dioxide (2m): yellow solid (14.3 mg, 41%); m.p. 167.5-168.3; ^1H NMR (400 MHz, CDCl₃) δ 9.58 (s, 1H), 8.79 (s, 1H), 8.07 (d, J = 7.3 Hz, 1H), 7.98 (t, J = 5.7 Hz, 2H), 7.82 (d, J = 7.5 Hz, 2H), 7.66 – 7.55 (m, 3H), 7.49 (d, J = 8.2 Hz, 1H), 7.42 (s, 1H), 2.59 (s, 3H); ^{13}C NMR (101 MHz, CDCl₃) δ 188.2, 151.2, 144.4, 134.7, 132.3, 131.2, 131.1, 129.8, 129.3, 128.6, 128.3, 128.2, 127.5, 127.2, 126.4, 125.5, 122.7, 122.5, 116.0, 22.1; **HR-MS (ESI)** calcd for $[\text{M} + \text{H}]^+$: C₂₀H₁₆NO₃S: 350.0845, found: 350.0843.




2-Isopropyl-6-methyl-2H-benzo[e][1,2]thiazine-4-carbaldehyde 1,1-dioxide (2n): yellow solid (15.9 mg, 60%); m.p. 93.5-95.3 °C; ^1H NMR (400 MHz, CDCl₃) δ 9.60 (s, 1H), 8.62 (s, 1H), 7.86 (d, J = 8.2 Hz, 1H), 7.37 (d, J = 7.8 Hz, 2H), 4.91 – 4.78 (m, 1H), 2.49 (s, 3H), 1.52 (d, J = 6.8 Hz, 6H); ^{13}C NMR (101 MHz, CDCl₃) δ 188.0, 145.4, 144.0, 129.3, 129.1, 126.7, 125.7, 122.1, 115.9, 49.3, 22.9, 22.0; **HR-MS (ESI)** calcd for $[\text{M} + \text{H}]^+$: C₁₃H₁₆NO₃S: 266.0845, found: 266.0846.




2-Cyclopropyl-6-methyl-2H-benzo[e][1,2]thiazine-4-carbaldehyde 1,1-dioxide (2o): yellow solid (17.6 mg, 67%); m.p. 109.5-110.3 °C; ^1H NMR (400 MHz, CDCl₃) δ 9.54 (s, 1H), 8.60 (s, 1H), 7.85 (d, J = 8.2 Hz, 1H), 7.51 – 7.27 (m, 2H), 3.56 – 3.12 (m, 1H), 2.48 (s, 3H), 1.22 – 1.03 (m, 4H); ^{13}C NMR (101 MHz, CDCl₃) δ 188.0, 150.7, 144.2, 129.4, 129.0, 127.0, 125.8, 122.3, 115.4, 30.4, 22.0, 6.8; **HR-MS (ESI)** calcd for $[\text{M} + \text{H}]^+$: C₁₃H₁₄NO₃S: 264.0689, found: 264.0689.



6-Methoxy-2-(p-tolyl)-2H-benzo[e][1,2]thiazine-4-carbaldehyde 1,1-dioxide (2p): yellow solid (23.0 mg, 70%); m.p. 150.5-151.3; ^1H NMR (400 MHz, CDCl₃) δ 9.55 (s, 1H), 8.43 (s, 1H), 7.90 (d, J = 8.9 Hz, 1H), 7.42 – 7.35 (m, 3H), 7.31 (d, J = 7.9 Hz, 2H), 7.09 (d, J = 8.9 Hz, 1H), 3.93 (s, 3H), 2.42 (s, 3H); ^{13}C NMR (101 MHz, CDCl₃) δ 188.2, 150.1, 146.4, 140.4, 139.3, 133.7, 130.6, 129.8, 129.1, 128.7, 128.3, 127.6, 127.5, 127.4, 124.6, 123.2, 116.1, 21.3; **HR-MS (ESI)** calcd for $[\text{M} + \text{H}]^+$: C₁₇H₁₆NO₄S: 330.0795, found: 330.0792.



6-Phenyl-2-(p-tolyl)-2H-benzo[e][1,2]thiazine-4-carbaldehyde 1,1-dioxide (2q): yellow solid (25.1 mg, 67%); m.p. 170.5-171.3 °C; ^1H NMR (400 MHz, CDCl₃) δ 9.63 (s, 1H), 9.13 (s, 1H), 8.08 (d, J = 8.3 Hz, 1H), 7.81 (d, J = 8.2 Hz, 1H), 7.69 (d, J = 7.3 Hz, 2H), 7.50 (t, J = 7.3 Hz, 2H), 7.45 (d, J = 7.5 Hz, 1H), 7.41 (d, J = 6.2 Hz, 3H), 7.33 (d, J = 7.7 Hz, 2H), 2.44 (s, 3H); ^{13}C NMR (101 MHz, CDCl₃) δ 188.2, 150.1, 146.4, 140.4, 139.3, 133.7, 130.6, 129.8, 129.1, 128.7, 128.3, 127.6, 127.5, 127.4, 124.6, 123.2, 116.1, 21.3; **HR-MS (ESI)** calcd for $[\text{M} + \text{H}]^+$: C₂₂H₁₈NO₃S: 376.1002, found: 376.0998.




6-Fluoro-2-(*p*-tolyl)-2H-benzo[e][1,2]thiazine-4-carbaldehyde

1,1-dioxide (2r): yellow solid (21.9 mg, 69%); m.p. 135.5-137.3 °C ;

¹H NMR (400 MHz, CDCl₃) δ 9.58 (s, 1H), 8.66 (d, *J* = 10.7 Hz, 1H), 8.09 – 7.99 (m, 1H), 7.45 (s, 1H), 7.41 (d, *J* = 7.7 Hz, 2H), 7.35 (d, *J* = 8.2 Hz, 2H), 7.30 (d, *J* = 8.9 Hz, 1H), 2.45 (s, 3H); **¹³C NMR** (101 MHz, CDCl₃) δ 187.8, 165.3 (d, *J* = 252 Hz, ¹*J*_{CF}) 150.6, 140.6,

133.3, 132.1 (d, *J* = 11 Hz, ³*J*_{CF}), 130.7, 127.4, 125.9 (d, *J* = 3 Hz, ³*J*_{CF}), 125.5 (d, *J* = 10 Hz, ³*J*_{CF}), 125.5, 116.5 (d, *J* = 24 Hz, ²*J*_{CF}), 115.0 (d, *J* = 3 Hz, ³*J*_{CF}), 113.0 (d, *J* = 26 Hz, ²*J*_{CF}), 21.3; **HR-MS (ESI)** calcd for [M + H]⁺: C₁₆H₁₃FNO₃S: 318.0595, found: 318.0593.




6-Chloro-2-(*p*-tolyl)-2H-benzo[e][1,2]thiazine-4-carbaldehyde

1,1-dioxide (2s): yellow solid (22.3 mg, 67%); m.p. 177.5-178.3 °C ;

¹H NMR (400 MHz, DMSO) δ 9.62 (s, 1H), 8.82 (s, 1H), 8.29 (s, 1H), 8.10 (d, *J* = 8.4 Hz, 1H), 7.79 (d, *J* = 8.1 Hz, 1H), 7.44 (dd, *J* = 20.2, 7.2 Hz, 4H), 2.40 (s, 3H); **¹³C NMR** (101 MHz, DMSO) δ 190.2, 153.0,

140.5, 139.2, 133.4, 131.2, 130.8, 129.5, 128.1, 127.9, 125.3, 125.1, 114.2, 21.2; **HR-MS (ESI)** calcd for [M + H]⁺: C₁₆H₁₃ClNO₃S: 334.0299, found: 334.0301.




7-Chloro-2-(*p*-tolyl)-2H-benzo[e][1,2]thiazine-4-carbaldehyde

1,1-dioxide (2t): yellow solid (13.3 mg, 40%); m.p. 159.5-161.3 °C ;

¹H NMR (400 MHz, CDCl₃) δ 9.60 (s, 1H), 8.88 (d, *J* = 8.8 Hz, 1H), 8.01 (s, 1H), 7.72 (d, *J* = 8.8 Hz, 1H), 7.40 (d, *J* = 5.5 Hz, 3H), 7.35 (d, *J* = 8.0 Hz, 2H), 2.46 (s, 3H); **¹³C NMR** (101 MHz, CDCl₃) δ 187.9,

149.6, 140.6, 134.7, 133.5, 133.4, 130.9, 130.7, 127.8, 127.7, 127.5, 122.5, 115.7, 21.3; **HR-MS (ESI)** calcd for [M + H]⁺: C₁₆H₁₃ClNO₃S: 334.0299, found: 334.0299.




6-Chloro-2-phenyl-2H-benzo[e][1,2]thiazine-4-carbaldehyde

1,1-dioxide (2u): yellow solid (17.5 mg, 55%); m.p. 202.5-203.3 °C ;

¹H NMR (400 MHz, DMSO) δ 9.65 (s, 1H), 8.83 (d, *J* = 1.9 Hz, 1H), 8.36 (s, 1H), 8.11 (d, *J* = 8.6 Hz, 1H), 7.80 (dd, *J* = 8.6, 2.0 Hz, 1H), 7.66 – 7.57 (m, 5H); **¹³C NMR** (101 MHz, DMSO) δ 190.3, 152.9, 139.2, 136.0, 131.2, 130.5, 130.4, 129.5, 128.2, 128.0, 125.3, 125.2,

114.4; **HR-MS (ESI)** calcd for [M + H]⁺: C₁₅H₁₁ClNO₃S: 320.0143, found: 320.0143.




6-Bromo-2-(*p*-tolyl)-2H-benzo[e][1,2]thiazine-4-carbaldehyde

1,1-dioxide (2v): yellow solid (24.1 mg, 64%); m.p. 187.5-188.3 °C ;

¹H NMR (400 MHz, CDCl₃) δ 9.59 (s, 1H), 9.11 (s, 1H), 7.88 (d, *J* = 8.5 Hz, 1H), 7.75 (d, *J* = 8.5 Hz, 1H), 7.44 (s, 1H), 7.40 (d, *J* = 8.0 Hz, 2H), 7.35 (d, *J* = 7.9 Hz, 2H), 2.46 (s, 3H); **¹³C NMR** (101 MHz,


CDCl₃) δ 187.7, 150.5, 140.7, 133.3, 131.9, 130.8, 130.7, 128.9, 128.6, 128.4, 127.4, 124.1, 114.9, 21.3; **HR-MS (ESI)** calcd for [M + H]⁺: C₁₆H₁₃BrNO₃S: 377.9794, found: 377.9796.




2-(*p*-Tolyl)-6-(trifluoromethyl)-2H-benzo[e][1,2]thiazine-4-carbaldehyde 1,1-dioxide (2w):

yellow solid (22.0 mg, 60%); m.p. 161.5-162.3 °C ; **¹H NMR** (400 MHz, CDCl₃) δ 9.64 (s, 1H), 9.26 (s, 1H), 8.16 (d, *J* = 8.3 Hz, 1H), 7.87 (d, *J* = 8.3 Hz, 1H), 7.50 (s, 1H), 7.38 (dd, *J* = 18.0, 8.2 Hz, 4H), 2.46 (s, 3H); **¹³C NMR** (101 MHz, CDCl₃) δ 187.7, 150.4,


140.8, 135.3, 135.0, 133.2, 132.2, 130.7, 130.1, 127.4, 125.4 (q, $J = 4$ Hz, $^3J_{CF}$), 123.6, 123.3 (d, $J = 272$ Hz, $^1J_{CF}$), 115.4, 21.3; **HR-MS (ESI)** calcd for $[M + H]^+$: $C_{17}H_{13}F_3NO_3S$: 368.0563, found: 368.0559.




7-Chloro-6-methyl-2-(p-tolyl)-2H-benzo[e][1,2]thiazine-4-carbaldehyde 1,1-dioxide (2x): yellow solid (19.1 mg, 55%); m.p. 191.5-193.3 °C; 1H NMR (400 MHz, $CDCl_3$) δ 9.56 (s, 1H), 8.79 (s, 1H), 7.97 (s, 1H), 7.38 (s, 1H), 7.35 (d, $J = 4.3$ Hz, 2H), 7.32 (d, $J = 8.0$ Hz, 2H), 2.53 (s, 3H), 2.43 (s, 3H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 188.0, 149.9, 142.5, 140.5, 135.0, 133.5, 130.6, 128.6, 128.2, 127.6, 127.5, 123.0, 115.6, 21.2, 20.8; **HR-MS (ESI)** calcd for $[M + H]^+$: $C_{17}H_{15}ClNO_3S$: 348.0456, found: 348.0454.



7-Fluoro-6-methyl-2-(p-tolyl)-2H-benzo[e][1,2]thiazine-4-carbaldehyde 1,1-dioxide (2y): yellow solid (18.9 mg, 57%); m.p. 199.5-200.3 °C; 1H NMR (400 MHz, $CDCl_3$) δ 9.55 (s, 1H), 8.77 (d, $J = 6.9$ Hz, 1H), 7.64 (d, $J = 8.2$ Hz, 1H), 7.37 (d, $J = 7.5$ Hz, 2H), 7.32 (d, $J = 5.4$ Hz, 3H), 2.43 (s, 6H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 188.1, 161.7, 149.4, 140.5, 133.5, 132.0 (d, $J = 18$ Hz, $^2J_{CF}$), 130.6, 129.6 (d, $J = 5$ Hz, $^3J_{CF}$), 128.8 (d, $J = 7$ Hz, $^3J_{CF}$), 125.4 (d, $J = 4$ Hz, $^3J_{CF}$), 109.2 (d, $J = 27$ Hz, $^2J_{CF}$), 21.3, 15.2; **HR-MS (ESI)** calcd for $[M + H]^+$: $C_{17}H_{15}FNO_3S$: 332.0751, found: 332.0746.




2-(p-Tolyl)-2H-pyrido[4,3-e][1,2]thiazine-4-carbaldehyde 1,1-dioxide (2z): yellow solid (15.0 mg, 50%); m.p. 141.5-142.3 °C; 1H NMR (400 MHz, $CDCl_3$) δ 10.71 (s, 1H), 9.05 – 8.89 (m, 1H), 8.28 (d, $J = 8.1$ Hz, 1H), 7.91 (s, 1H), 7.53 – 7.47 (m, 1H), 7.33 (q, $J = 8.0$ Hz, 4H), 2.43 (s, 3H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 187.9, 153.5, 148.6, 142.1, 140.6, 133.3, 131.4, 130.6, 127.5, 125.6, 122.2, 114.7, 21.3; **HR-MS (ESI)** calcd for $[M + H]^+$: $C_{15}H_{13}N_2O_3S$: 301.0641, found: 301.0635.



6-Methyl-3-phenyl-2-(p-tolyl)-2H-benzo[e][1,2]thiazine-4-carbaldehyde 1,1-dioxide (2-1z): light yellow liquid; 1H NMR (400 MHz, $CDCl_3$) δ 9.48 (s, 1H), 8.15 (d, $J = 8.6$ Hz, 1H), 8.06 (s, 1H), 7.49 (t, $J = 7.4$ Hz, 1H), 7.39 (t, $J = 7.6$ Hz, 2H), 7.32 (d, $J = 7.6$ Hz, 2H), 7.26 (d, $J = 8.3$ Hz, 2H), 7.22 (d, $J = 8.7$ Hz, 1H), 7.04 (d, $J = 8.1$ Hz, 2H), 2.41 (s, 3H), 2.27 (s, 3H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 188.1, 150.8, 145.6, 135.5, 135.3, 134.8, 132.0, 130.2, 130.0, 129.7, 128.9, 128.3, 128.1, 127.7, 127.5, 127.0, 126.2, 121.9, 121.2, 114.9, 21.6, 21.4; **HR-MS (ESI)** calcd for $[M + H]^+$: $C_{23}H_{20}NO_3S$: 390.1158, found: 390.1148.

3. Synthetic applications of this transformation




Preparation of 2-(4,4-dicyano-1-(p-tolylamino)buta-1,3-dien-2-yl)-4-methylbenzenesulfonic acid 3a.⁵

A mixture of compound **2a** (0.30 mmol), piperidine (0.5 mL) and malononitrile (0.30 mmol) in ethanol (5.0 mL) was heated under reflux for 3 hours. The mixture was then cooled to 25-30 °C and condensed under reduced pressure to form the corresponding oil. The residue was purified by

flash column chromatography on silica gel to afford the desired product **3a**. Yellow solid (17.1 mg, 45%); m.p. 173.5-1474.3 °C; $^1\text{H NMR}$ (400 MHz, DMSO) δ 12.66 (s, 1H), 9.93 (s, 1H), 7.92 (d, J = 8.1 Hz, 1H), 7.75 (d, J = 2.5 Hz, 1H), 7.52 (d, J = 2.5 Hz, 1H), 7.39 (d, J = 8.1 Hz, 1H), 7.18 (s, 1H), 6.99 (d, J = 8.2 Hz, 2H), 6.79 (d, J = 8.3 Hz, 2H), 2.34 (s, 3H), 2.19 (s, 3H); $^{13}\text{C NMR}$ (101 MHz, DMSO) δ 160.0, 150.4, 143.9, 141.4, 135.9, 135.0, 134.8, 134.3, 133.4, 130.3, 130.0, 129.6, 120.0, 116.9, 116.3, 102.8, 21.1, 20.7; **HR-MS (ESI)** calcd for $[\text{M} + \text{H}]^+$: $\text{C}_{20}\text{H}_{18}\text{N}_3\text{O}_3\text{S}$: 380.1063, found: 380.1060.


Preparation of 4-(1-hydroxyprop-2-yn-1-yl)-6-methyl-2-(p-tolyl)-2H-benzo[e][1,2]thiazine1,1-dioxide **3b.**⁶



To an ice-cold solution of **2a** (0.2 mmol) in anhydrous THF (5 mL) under Ar atmosphere was added ethynylmagnesium bromide (1.5 eq., 0.5 M in THF), and the reaction mixture was stirred for 4 h (monitored by TLC analysis) at 0 °C. Reaction mixture was diluted with saturated aq. NH_4Cl (10 mL) and extracted with ethyl acetate (3×10 mL). The combined organic layers were washed with brine (10 mL) and dried over MgSO_4 . Evaporation of the solvent and purification of the crude mixture by flash column chromatography (10:1, hexane: EtOAc) gave the corresponding product **3b** in 68 % yields. Yellow solid (23.1 mg, 68%); m.p. 141.5-142.3 °C; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.77 (d, J = 8.1 Hz, 1H), 7.60 (s, 1H), 7.25 (d, J = 8.1 Hz, 1H), 7.17 (dd, J = 18.5, 8.1 Hz, 4H), 7.08 (s, 1H), 5.55 (s, 1H), 2.86 (s, 1H), 2.58 (s, 1H), 2.40 (s, 3H), 2.30 (s, 3H); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 143.1, 138.8, 134.7, 132.0, 131.3, 130.1, 129.0, 128.8, 127.1, 124.8, 122.6, 116.9, 81.8, 76.2, 61.0, 22.0, 21.2; **HR-MS (ESI)** calcd for $[\text{M} + \text{H}]^+$: $\text{C}_{19}\text{H}_{19}\text{NO}_3\text{S}$: 340.1007, found: 340.0817.


V. Control experiments for mechanistic investigation

1. The effect of the radical trapper TEMPO on the intramolecular carbo-oxygenation of alkyne **1a**



An oven dried reaction tube containing a PTFE-coated stir bar was charged sequentially with **TEMPO** (2.0 equiv, 31.2 mg), *N*-propargyl-*N*-tosylamide **1a** (0.10 mmol, 29.9 mg), Eosin Y (2.5 mol %, 1.8 mg), K_2CO_3 (1.5 equiv, 20.7 mg), PhSPh (0.10 mmol, 21.8 mg) and H_2O (0.50 mmol, 9 μL), followed by the addition of DCE (2.0 mL) under air. Then the mixture was stirred and irradiated by 2×30 W blue LEDs at room temperature for 24 h. No desired product **2a** was detected, and the reaction was completely inhibited.

2. H/D exchange about the intramolecular carbo-oxygenation of alkyne **1a**



N-Propargyl-*N*-tosylamide (**1a**, 0.10 mmol, 29.9 mg), Eosin Y (2.5 mol %, 1.8 mg), K₂CO₃ (1.5 equiv, 20.7 mg), PhSSPh (0.10 mmol, 21.8 mg) and **D₂O** (0.50 mmol, 9 uL), followed by the addition of DCE (2.0 mL) under air, and the reaction vessel was irradiated with 2 × 30 W blue LED at room temperature for 24 h. After the reaction was complete, the reaction mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography and preparative TLC to afford the corresponding product **2a**, ¹H NMR spectrum of **d-2a** indicated that no H/D exchange of formyl Csp²-H bond was observed (**Figure S-1**).





Figure S-1. ¹H NMR analysis of **d-2a**

3. ¹⁸O Isotope tracing experiment



N-Propargyl-*N*-tosylamide (**1a**, 0.10 mmol, 29.9 mg), Eosin Y (2.5 mol %, 1.8 mg), K₂CO₃ (1.5 equiv, 20.7 mg), PhSSPh (0.10 mmol, 21.8 mg) and H₂O (0.50 mmol, 9 uL), followed by the addition of DCE (2.0 mL), and the reaction vessel was irradiated with 2 × 30 W blue LED at room temperature for 24 h under the atmosphere of ¹⁸O₂. After the reaction was complete, the reaction mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography and preparative TLC to afford the corresponding product **2a-¹⁸O**, which

was characterized by ^1H NMR (Figure S-2), ^{13}C NMR (Figure S-3) and HR-MS (Figure S-4).




Figure S-2. ^1H NMR analysis of **2a- ^{18}O** isotopic labeled product




Figure S-3. ^{13}C NMR analysis of **2a- ^{16}O** and **2a- ^{18}O**






Figure S-4. HR-MS analysis of **2a-¹⁶O** and **2a-¹⁸O**


4. The procedure for the preparation of **d₅-1d**




Benzene-*d*₆ (2.0 g, 25 mmol) (99.5% isotopic purity) was dissolved in 10 mL of CHCl₃, and cooled under argon to 0 °C. Chlorosulfuric acid (13 mL) was added during 10 min at the same temperature. The ice-salt bath was removed and the mixture was still stirred for 45 min at room temperature. The mixture was then diluted with 50 mL of CH₂Cl₂ and poured onto 100 mL of ice water. The organic layer was separated, washed with water (2 × 40 mL), dried with MgSO₄, and evaporated to give a colorless oil. Purification was carried out by distillation to give *d*₅-benzenesulfonyl chloride as clear colorless oil.⁷



To a solution of the aniline (1.0 equiv) in anhydrous DCM (20 mL) at 0 °C was added triethylamine (1.2 equiv) and *d*₅-benzenesulfonyl chloride (1.1 equiv). The reaction mixture was stirred at room temperature until the reaction was completed (monitored by TLC). Then water (50 mL) was carefully added, and the mixture was extracted by DCM (3 × 20 mL). The combined organic layers were dried over Na₂SO₄ and concentrated to dryness under reduced pressure to obtain a residue, then purified through flash chromatography on silica gel with ethyl acetate/petroleum (v/v = 25/1) as the eluent to afford the desired *d*₅-amides.



Finally to a solution of d_5 -amides (1.0 equiv) in anhydrous DMF (20 mL) was added sodium hydride (60% dispersion in mineral oil, 1.1 equiv) at 0 °C under Ar. The reaction was stirred for 15 minutes at the same temperature and then 3-bromo-propyne (1.2 equiv) was slowly added *via* a syringe. The mixture was stirred at room temperature until the reaction completed and then quenched with a saturated solution of NH_4Cl (20 mL). The combined organic phases were washed with water (3×20 mL) and brine (20 mL), dried over anhydrous MgSO_4 and concentrated to obtain the corresponding residue, which was then purified through flash chromatography on silica gel with ethyl acetate/petroleum (v/v = 50/1) as the eluent to afford the desired product d_5 -1d.



***N*-(prop-2-yn-1-yl)-*N*-(*p*-tolyl)benzenesulfonamide (d_5 -1d):** ^1H NMR (400 MHz, CDCl_3) δ 7.67 (s, 0.32H), 7.56 (s, 0.17H), 7.44 (s, 0.33H), 7.15 – 7.04 (m, 4H), 4.42 (s, 2H), 2.33 (s, 3H), 2.15 (d, $J = 1.3$ Hz, 1H); ^{13}C NMR (101 MHz, CDCl_3) δ 138.4, 136.5, 129.8, 128.42, 78.1, 73.8, 41.3, 21.2; **HR-MS (ESI)** calcd for $[\text{M} + \text{Na}]^+$: $\text{C}_{16}\text{H}_{10}\text{D}_5\text{NO}_2\text{SNa}$:

313.1030, found: 313.1057.





Figure S-5. ^1H NMR analysis of d_5 -1d

5. Kinetic isotope effect for this transformation



A flame-dried 5 ml Schlenk tube equipped with a magnetic stirrer bar was charged sequentially with *N*-propargyl-*N*-tosylamide (**1d**: 0.10 mmol, 28.5 mg or **d5-1d**: 0.1 mmol, 29.9 mg), Eosin Y (2.5 mol %, 1.8 mg), K_2CO_3 (1.5 equiv, 20.7 mg), PhSSPh (0.10 mmol, 21.8 mg) and H_2O (0.50 mmol, 9.0 μ L), followed by the addition of DCE (2.0 mL) under air. Then the mixture was stirred and irradiated with 2 x 30 W blue LEDs at room temperature. An aliquot of each reaction mixture was taken at 2 h, 4 h, 6 h, 8 h and 10 h. After the solvent of each aliquot (0.5 mL) was removed under reduced pressure conditions and analyzed by 1H NMR spectrum (see **Figure S-4** and **Figure S-5**). The relative 1H NMR yield of **1d** and **d5-1d** were shown in **Table 1-6**. A sample plot of the initial rate data for the reaction of both **1d** and **d5-1d** was shown in **Figure S-6** and **Figure S-7**. The reaction progress in the early stage (0-10 h) indicated a kinetic isotope effect (KIE) of 1.0.




Figure S-6. The conversion of **1d** was monitored by 1H NMR method




Figure S-7. The conversion of $d5-1d$ was monitored by ^1H NMR method

Table S-6. The relative yields (%) of $2d$ and $d4-2d$ was monitored by ^1H -NMR method

Time (h)	0	2	4	6	8	10
^1H NMR yield of $2d$ from $1d$ (%)	0	9.9	28.6	56.1	66.7	79.2
^1H NMR yield of $d4-2d$ from $d5-1d$ (%)	0	7.4	39.8	41.5	72.7	79.1




Figure S-8 The plot of initial rates for the conversion of $1d$






Figure S-9. The plot of initial rates for the conversion of *d5-1d*

6. The PhSSPh-promoted intramolecular carboxygenation of alkyne **1a**



An oven dried reaction tube containing a PTFE-coated stir bar was charged sequentially with *N*-propargyl-*N*-tosylamide (**1a**, 0.10 mmol, 30 mg), PhSSPh (0.10 mmol, 21.8 mg), K_2CO_3 (1.5 equiv, 20.7 mg) and H_2O (0.50 mmol, 9.0 μ L), followed by the addition of DCE (2.0 mL) under air. Then the mixture was stirred and irradiated with 2×30 W blue LEDs at room temperature for 24 h. The solvent was then evaporated to dryness, and the resulting residue was purified by silica gel column chromatography to provide pure product **2a** in 48% yield.

7. The photocatalyzed intramolecular carboxygenation of alkynes **1a** under argon



A flame-dried 5 mL Schlenk tube equipped with a magnetic stirrer bar was charged sequentially with *N*-propargyl-*N*-tosylamides (**1**, 0.10 mmol, 29.9 mg), Eosin Y (2.5 mol %, 1.8 mg), K_2CO_3 (1.5 equiv, 20.7 mg), PhSSPh (0.10 mmol, 21.8 mg) and H_2O (0.50 mmol, 9.0 μ L), followed by the addition of DCE (2.0 mL) under argon. Then the mixture was stirred and irradiated with 2×30 W blue LEDs at room temperature for 48 h. The residue was purified by flash column chromatography on silica gel (petrol ether/EtOAc = 50/1) to afford the vinyl thioether (*Z*)-**4a**. A yellow liquid (25.6 mg, 63%); 1H NMR (500 MHz, $CDCl_3$) δ 7.47 (d, J = 8.0 Hz, 2H), 7.30 (m, 3H), 7.20 (m, 3H), 7.03 (s, 2H), 6.96 (d, J = 1.5 Hz, 1H), 6.95 (d, J = 1.0 Hz, 1H), 6.23 (s, 1H), 4.51 (s, 2H), 2.41 (s, 3H), 2.32 (s, 3H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 143.2, 138.9, 137.1, 134.2, 133.8, 130.8, 130.6, 129.6, 129.5, 128.6, 128.0, 126.4, 125.5, 124.9, 124.7, 53.6, 21.8, 21.0; HR-MS (ESI) calcd for $[M + Na]^+$: $C_{23}H_{21}NO_2S_2Na$: 430.0911, found: 430.0909.





Figure S-10. The ^1H - ^1H NOE spectrum of (Z)-4a

8. The vinyl thioether (Z)-4a converted to target compound 2a under standard conditions



The vinyl thioether (Z)-4a (40.7 mg, 0.1 mmol), Eosin Y (2.5 mol %, 1.8 mg), PhSSPh (21.8 mg, 0.1 mmol) and K_2CO_3 (20.7 mg, 1.5 equiv) were taken in an oven dried round bottom flask with a magnetic stir, and then, dry DCE (2 mL) was added. Then the mixture was stirred and irradiated with 2×30 W blue LEDs at room temperature for 24 h. The residue was purified by flash column chromatography on silica gel (petrol ether/EtOAc = 20/1) to afford the target compound 2a (54% yield).

9. Luminescence Quenching Experiments

Fluorescence spectra was collected on Hitachi Fluorescence Spectrophotometer F-7000 for all experiments. All Eosin Y solutions were excited at 539 nm^8 and the emission intensity was collected at 450 nm . In a typical experiment, the emission spectrum of a $1 \times 10^{-4} \text{ M}$ solution of Eosin Y in CH_3CN was collected. The significant decrease of Eosin Y luminescence could be observed in the presence of PhSSPh and O_2 . On the contrary, only a slightly decrease of Eosin Y luminescence was observed in the presence of substrate 1a and O_2 (see Figure S-11).





Figure S-11. Eosin Y emission quenching by **1a** and PhSSPh

10. Light On/Off Experiments

We performed the light ON/OFF experiments on the model reaction using 4-methyl-*N*-(prop-2-yn-1-yl)-*N*-(*p*-tolyl)benzenesulfonamide **1a** and the result are shown below.



The data showed that the formation of the desired product was halted during the light off period and product formation only occurred during constant irradiation with blue light. This experimental may indicate that a extended radical chain process is not likely and it manifests the photoredox catalytic mechanism.




Figure S-12. Light ON/OFF experiment for the reaction of **1a**

VI. Single Crystal Structure and Crystallographic Data for 2u




Figure S-13. The single crystal structure of **2u** (the ellipsoid contour probability level is 30%)

Table S-7. Crystal data and structure refinement for **2u**

Identification code	C1
Empirical formula	C ₁₅ H ₁₀ ClNO ₃ S
Formula weight	319.75
Temperature/K	100.00(10)
Crystal system	triclinic
Space group	P-1
a/Å	7.0797(4)
b/Å	8.5758(5)
c/Å	10.9983(6)
α/°	93.142(5)
β/°	91.207(4)
γ/°	91.822(5)
Volume/Å ³	666.24(7)
Z	2
ρ _{calc} /cm ³	1.594
μ/mm ⁻¹	0.452
F(000)	328.0
Crystal size/mm ³	0.13 × 0.12 × 0.11
Radiation	MoKα (λ = 0.71073)
2θ range for data collection/°	4.76 to 58.876
Index ranges	-9 ≤ h ≤ 9, -11 ≤ k ≤ 11, -13 ≤ l ≤ 15
Reflections collected	9057
Independent reflections	3225 [R _{int} = 0.0439, R _{sigma} = 0.0571]
Data/restraints/parameters	3225/0/190

VII. Reference


- Wang, J. J.; Li, F.; Pei, W. L.; Yang, M.; Wu, Y.; Ma, D.; Zhang, F.; Wang, J. *Tetrahedron Lett.* **2018**, 59, 1902–1905.
- Alaoui, S.; Dufies, M.; Driowya, M.; Demange, L.; Bougrin, K.; Robert, G.; Auberger, P.; Pagès, G.; Benhida, R. *Bioorg. Med. Chem. Lett.* **2007**, 17, 6656.
- Murase, H.; Senda, K.; Senoo, M.; Hata, T.; Urabe, H. *Chem–Eur J.* **2014**, 20, 317–322.
- Hedouin, J.; Schneider, C.; Gillaizeau, I.; Hoarau, C. *Org. Lett.* **2018**, 20, 6027–6032.
- Shanmuganathan, T.; Prince, A. A. M.; Dhatchanamoorthy, N.; Parthasarathy, K.; Venugopal,

M. *Arkivoc* **2017**, part v, 67–79.


6. Chinta, B. S.; Baire, B. *J. Org. Chem.* **2015**, *80*, 10208–10217.
7. Kong, W.; Merino, E.; Nevado, C. *Angew. Chem., Int. Ed.* **2014**, *53*, 5078–5082.
8. Marzo, L.; Pagire, S. K.; Reiser, O.; Kçnig, B. *Angew. Chem., Int. Ed.* **2018**, *57*, 10034–10072.

Appendix II: Spectral copies of ^1H and ^{13}C NMR of compounds


^1H NMR spectrum (400 MHz, CDCl_3) of **1a**




^{13}C NMR spectrum (100 MHz, CDCl_3) of **1a**




¹H NMR spectrum (400 MHz, CDCl₃) of **1b**




¹³C NMR spectrum (100 MHz, CDCl₃) of **1b**




^1H NMR spectrum (400 MHz, CDCl_3) of **1c**




^{13}C NMR spectrum (100 MHz, CDCl_3) of **1c**




^1H NMR spectrum (400 MHz, CDCl_3) of **1d**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1d**




^1H NMR spectrum (400 MHz, CDCl_3) of **1e**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1e**




^1H NMR spectrum (400 MHz, CDCl_3) of **1f**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1f**




^1H NMR spectrum (400 MHz, CDCl_3) of **1g**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1g**




^1H NMR spectrum (400 MHz, CDCl_3) of **1h**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1h**




^1H NMR spectrum (400 MHz, CDCl_3) of **1i**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1i**




^1H NMR spectrum (400 MHz, CDCl_3) of **1j**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1j**




^1H NMR spectrum (400 MHz, CDCl_3) of **1k**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1k**




^1H NMR spectrum (400 MHz, CDCl_3) of **11**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **11**




^1H NMR spectrum (400 MHz, CDCl_3) of **1m**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1m**




^1H NMR spectrum (400 MHz, CDCl_3) of **1n**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1n**




^1H NMR spectrum (400 MHz, CDCl_3) of **1o**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1o**




¹H NMR spectrum (400 MHz, CDCl₃) of **1p**




¹³C NMR spectrum (400 MHz, CDCl₃) of **1p**




^1H NMR spectrum (400 MHz, CDCl_3) of **1q**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1q**




^1H NMR spectrum (400 MHz, CDCl_3) of **1r**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1r**




^1H NMR spectrum (400 MHz, CDCl_3) of **1s**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1s**




^1H NMR spectrum (400 MHz, CDCl_3) of **1t**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1t**




^1H NMR spectrum (400 MHz, CDCl_3) of **1u**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1u**




^1H NMR spectrum (400 MHz, CDCl_3) of **1v**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1v**




^1H NMR spectrum (400 MHz, CDCl_3) of **1w**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1w**




^1H NMR spectrum (400 MHz, CDCl_3) of **1x**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1x**




^1H NMR spectrum (400 MHz, CDCl_3) of **1y**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1y**




^1H NMR spectrum (400 MHz, CDCl_3) of **1z**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1z**




^1H NMR spectrum (400 MHz, CDCl_3) of **1-1z**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1-1z**




¹H NMR spectrum (400 MHz, CDCl₃) of **1-1a**




¹³C NMR spectrum (400 MHz, CDCl₃) of **1-1a**




^1H NMR spectrum (400 MHz, CDCl_3) of **1-1b**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1-1b**




^1H NMR spectrum (400 MHz, CDCl_3) of **1-1c**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **1-1c**




^1H NMR spectrum (400 MHz, CDCl_3) of **2a**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2a**




^1H NMR spectrum (400 MHz, CDCl_3) of **2b**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2b**




^1H NMR spectrum (400 MHz, CDCl_3) of **2c**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2c**




^1H NMR spectrum (400 MHz, CDCl_3) of **2d**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2d**




^1H NMR spectrum (400 MHz, CDCl_3) of **2e**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2e**




^1H NMR spectrum (400 MHz, CDCl_3) of **2f**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2f**




^1H NMR spectrum (400 MHz, CDCl_3) of **2g**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2g**




^1H NMR spectrum (400 MHz, CDCl_3) of **2h**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2h**




^1H NMR spectrum (400 MHz, CDCl_3) of **2i**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2i**




^1H NMR spectrum (400 MHz, CDCl_3) of **2j**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2j**




^1H NMR spectrum (400 MHz, CDCl_3) of **2k**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2k**




^1H NMR spectrum (400 MHz, CDCl_3) of **2I**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2I**




^1H NMR spectrum (400 MHz, CDCl_3) of **2m**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2m**




^1H NMR spectrum (400 MHz, CDCl_3) of **2n**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2n**




^1H NMR spectrum (400 MHz, CDCl_3) of **2o**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2o**




^1H NMR spectrum (400 MHz, CDCl_3) of **2p**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2p**




^1H NMR spectrum (400 MHz, CDCl_3) of **2q**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2q**




^1H NMR spectrum (400 MHz, CDCl_3) of **2r**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2r**




^1H NMR spectrum (400 MHz, DMSO) of 2s




^{13}C NMR spectrum (400 MHz, DMSO) of 2s



^1H NMR spectrum (400 MHz, CDCl_3) of **2t**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2t**




^1H NMR spectrum (400 MHz, DMSO) of **2u**




^{13}C NMR spectrum (400 MHz, DMSO) of **2u**




^1H NMR spectrum (400 MHz, CDCl_3) of **2v**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2v**




^1H NMR spectrum (400 MHz, CDCl_3) of **2w**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2w**




^1H NMR spectrum (400 MHz, CDCl_3) of **2x**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2x**




^1H NMR spectrum (400 MHz, CDCl_3) of **2y**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2y**




^1H NMR spectrum (400 MHz, CDCl_3) of **2z**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2z**




^1H NMR spectrum (400 MHz, CDCl_3) of **2-1z**




^{13}C NMR spectrum (400 MHz, CDCl_3) of **2-1z**




¹H NMR spectrum (400 MHz, DMSO) of **3a**




¹³C NMR spectrum (400 MHz, DMSO) of **3a**




^1H NMR spectrum (400 MHz, CDCl_3) of **3b**



^{13}C NMR spectrum (400 MHz, CDCl_3) of **3b**



^1H NMR spectrum (500 MHz, CDCl_3) of (Z)-4a



^{13}C NMR spectrum (500 MHz, CDCl_3) of (Z)-4a

